SELLAS Life Sciences Group, Inc., was incorporated in Delaware on April 3, 2006 as Argonaut Pharmaceuticals, Inc. In December 2017, the Company completed a business combination with a privately held Bermuda exempted company and changed its name to "SELLAS Life Sciences Group, Inc.". The company is a late-stage clinical biopharmaceutical company focused on developing new therapies for a variety of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy for nephroblastoma 1 or WT1 antigen, and GFH009, a highly selective small molecule cyclin-dependent kinase 9, or CDK 9 inhibitor. The company's lead product candidate, GPS, a cancer immunotherapy agent licensed from Memorial Sloan Kettering Cancer Center (MSK), targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a direct immune agent, GPS has the potential to be used as monotherapy or in combination with immunotherapeutics to address a wide range of hematological, or hematological, cancer and solid tumor indications.
